Dave Kauppi is the editor of The Exit Strategist Newsletter and Managing Director with MidMarket Capital Advisors, LLC. providing corporate finance and intermediary services to entrepreneurs in healthcare and a variety of industries. MMCA counsels clients in M&A, exit and succession planning, valuations, sales and acquisitions. Dave graduated from The Wharton School of Business, University of Pennsylvania with a BS in Economics /Finance. He received an MBA from DePaul University.
Tuesday, January 6, 2015
Generic Drug Manufacturer Unlocking the Hidden Value in Drug Portfolios
There is huge untapped potential in the pharma and Bio Tech industry in drug repositioning (identifying new uses for existing drugs). Up until now the process has been largely the result of serendipity or accidental discovery and therefore has not had much impact outside of a few success stories like Viagra. If you think about Aspirin, we have discovered 10 additional uses but it has taken mankind 89 years to do so. With the CureHunter discovery engine we have compressed that process down to a couple of weeks. We are looking for a few JV partners to unlock the hidden value in drug portfolios.
Dave Kauppi is a Merger and Acquisition Advisor and Managing Director of MidMarket Capital, providing business broker and investment banking services to owners in the sale of information technology companies. To view our lists of buyers and sellers click to visit our Web Site MidMarket Capital
Subscribe to:
Posts (Atom)